Alembic Pharmaceuticals has informed that the Company has successfully completed the US Food and Drug Administration (USFDA) Remote Regulatory Assessment (RRA) for its Bioequivalence Facility, Bio-analytical division, located at Vadodara, without any observations. The RRA was conducted from 22nd August, 2022 to 26th August, 2022.
The above information is a part of company’s filings submitted to BSE.